All News
#ACR21 #pedsrheum
With so much work ahead, what to tackle first?
1⃣Gathering and organizing the top 10 priorities in cSLE https://t.co/H3ASXAfM4m
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Rheum Radiology Bootcamp
Rheum dz = increased risk of lung cancer
Important note: Fleischner recs for incidental nodules do not apply to immunosuppressed patients. Stay on alert for malignancy.
#ACR2021
Pedro Castillo _Castillo_Pedro ( View Tweet)
Consider baseline risk of lung cancer. Scleroderma and RA in particular at increased risk => lower threshold for getting initial CT. For incidental nodule, consider rescreening at 6-12 months, then space out.
#ACR2021
Pedro Castillo _Castillo_Pedro ( View Tweet)
Brepocitinib (TYK2/JAK1i) superior to PBO in PsA at week 16, w/ improvements in refractory domains continuing over 52 weeks. There were more AEs in the brepocitinib groups vs PBO over 16 weeks. Abs 0488 #ACR21 #RheumNow @RheumNow https://t.co/umk4REJwkS https://t.co/JYZVR3jyY5
Dr. Rachel Tate uptoTate ( View Tweet)
BE AGILE: No new safety signals in AS pts treated with BKZ ( IL-17F/IL-17Ai) and remains efficacious as a potential treatment in AS. Abs 0491 #ACR21 #RheumNow @RheumNow https://t.co/fGT8n5Hx9C https://t.co/rjPTla7JId
Dr. Rachel Tate uptoTate ( View Tweet)
Common sense to ⬇️#rheumatoidarthritis 6S412 G Burmester summarizes decades of RA research - avoidance strategies =healthy lifestyle. ?asked is sero+RA diff than seronegative? Maybe. other Abs likely exist @RheumNow #ACR21 #ACRBest https://t.co/RT3dHDfdWp
Janet Pope Janetbirdope ( View Tweet)
After elegantly laying out the sophisticated science at #ACR21, Gerd Burmester finishes with this:
Without waiting, 11 things we can actually do now to reduce our chance of RA
@The_IMJ Ranjeny Thomas and @lynmarch1 et al
@RheumNow https://t.co/Be1Jyw9FOo
David Liew drdavidliew ( View Tweet)
I'm wearing my badge, just in case... #RheumPix https://t.co/UvgCinq8Bn
Dr. John Cush RheumNow ( View Tweet)
Spinal involvement: fine, symmetric syndesmophytes (axSpA) vs bulky, asymmetric syndesmophytes (axPsA)
#ACR21 https://t.co/7leGTjm4fb
Rheum Cat rheum_cat ( View Tweet)
@AUGarren @DavidLeverenz demonstrate significant gaps in DMARD lab safety monitoring in telehealth setting. Small improvement over time but still <50% 😱 Abstr#0146 #ACR21 @RheumNow https://t.co/FDp7ZwzfO5
Richard Conway RichardPAConway ( View Tweet)
Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement
⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo
⬇️MMP3 (associated with joint damage), C4M
Abs#490
#ACR21
@RheumNow
https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x
Robert B Chao, MD doctorRBC ( View Tweet)
Skin Findings in Patients of Color with Rheumatic Disease #ACR21.
Don't miss lupus panniculitis. https://t.co/kM6XbFtNoW
Sali Merjanah SMerjanah ( View Tweet)
Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment
⬆️ACR20, 50, 70 response vs. pbo
⬆️secondary outcomes vs. pbo
⬆️serious AE vs. pbo, ⬆️zoster
⭐️no MACE/VTE/death reported
Abs#488
#ACR21
@RheumNow
https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t
Robert B Chao, MD doctorRBC ( View Tweet)
OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infiltrates, Sweets, Arthritis. Genetic adult auto inflammatory syndrome ⬆️Men Rx steroids, then IL6i, etc. IL1i has ⬆️skin reactions 6S410 #ACR21 #gamechanger @RheumNow #ClinicalPearl https://t.co/OYRi1yAal5
Janet Pope Janetbirdope ( View Tweet)
Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA studies. From Dr. Atul Deodhar's presentation at
#ACR21 6S403 session @RheumNow https://t.co/Iv0LCNob5J
Pedro Castillo _Castillo_Pedro ( View Tweet)
Abst 0482
Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated with significantly lower risk of developing #OA and time to joint replacement
#ACR21 @RheumNow https://t.co/a00g3HMrM0
Akhil Sood MD AkhilSoodMD ( View Tweet)
🚨 DESIRES study. DB RCT in systemic sclerosis. Significant benefit of Rituximab in Rodnan skin score and FVC! Abstr#496 #ACR21 @RheumNow #ACRBest https://t.co/Ta6Cq8XZie
Richard Conway RichardPAConway ( View Tweet)
Lots of excellent abstracts at #ACR21 on assessment & impact of #comorbidities & #multimorbidity in RA, some discussed in this article @RheumNow:
https://t.co/WXgv1GmHD6
Featured abstracts:
#0798 https://t.co/02BRqYp9Yk
#1450 https://t.co/iG2s2Cy8Q0
#1924 https://t.co/qHws6ALENH
Links:
- Towards better assessment and management of multimorbidity | RheumNow
- The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its…
- Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-…
- Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utiliza…
Mrinalini Dey DrMiniDey ( View Tweet)
Cool talk by P Grayson - how to design ANCA vasculitis RCTs with biomarkers, umbrella/basket RCT designs to treat pts MORE likely to respond. Also for an individual, following ANCA is not that helpful for altering Rx Take a look at this session GS401 #ACR21 #ACRBest @RheumNow https://t.co/nrapO9i4gw
Janet Pope Janetbirdope ( View Tweet)
Abst 0478
Binvignat et al performed hierarchical clustering analysis based on cardinal symptoms in hand OA
- Identified 5 Phenotypes
- Symptoms correlated with metabolic syndrome, joint destruction & physical and psychological burden
#ACR21 @RheumNow https://t.co/O9hweqNIS8
Akhil Sood MD AkhilSoodMD ( View Tweet)
